Access comprehensive financial analyses and make smarter investments - get the Manual of Investments on Amazon!

THC

What Do You Need to Know About Tenet Healthcare (THC) Before Investing?

Large-cap Health Care company Tenet Healthcare has moved 0.1% so far today on a volume of 246,353, compared to its average of 1,701,580. In contrast, the S&P 500 index moved -2.0%.

Tenet Healthcare trades -19.17% away from its average analyst target price of $171.28 per share. The 22 analysts following the stock have set target prices ranging from $134.0 to $217.0, and on average have given Tenet Healthcare a rating of buy.

If you are considering an investment in THC, you'll want to know the following:

  • Tenet Healthcare's current price is -30.6% below its Graham number of $199.52, which implies the stock has a margin of safety

  • Tenet Healthcare has moved 19.3% over the last year, and the S&P 500 logged a change of 10.8%

  • Based on its trailing earnings per share of 32.71, Tenet Healthcare has a trailing 12 month Price to Earnings (P/E) ratio of 4.2 while the S&P 500 average is 29.3

  • THC has a forward P/E ratio of 12.1 based on its forward 12 month price to earnings (EPS) of $11.46 per share

  • Its Price to Book (P/B) ratio is 3.12 compared to its sector average of 3.19

  • Tenet Healthcare Corporation operates as a diversified healthcare services company in the United States.

  • Based in Dallas, the company has 74,480 full time employees and a market cap of $13.06 Billion.

The above analysis is intended for educational purposes only and was performed on the basis of publicly available data. It is not to be construed as a recommendation to buy or sell any security. Any buy, sell, or other recommendations mentioned in the article are direct quotations of consensus recommendations from the analysts covering the stock, and do not represent the opinions of Market Inference or its writers. Past performance, accounting data, and inferences about market position and corporate valuation are not reliable indicators of future price movements. Market Inference does not provide financial advice. Investors should conduct their own review and analysis of any company of interest before making an investment decision.

IN FOCUS